Citi analyst David Hoang initiated coverage of Voyager Therapeutics with a Buy rating and $16 price target. The stock has gained 26% over the past month as the market gains a greater appreciation of the company’s capabilities in the CNS space following recent deal activity with Novartis in January, the analyst tells investors in a research note. Folllowing a strategic shift in 2021 and under leadership of CEO Al Sandrock since March 2022, the compay has emerged as a premier player in CNS gene therapies with its proprietary TRACER platform and next-gen AAV capsids, backed by a strong balance sheet, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics reports Q4 EPS $1.25, consensus (29c)
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
- Voyager Therapeutics reports selection of gene therapy development candidate
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
- VYGR Upcoming Earnings Report: What to Expect?
